Regeneron Pharmaceuticals Inc recalls Libtayo (cemiplimab-rwlc) Injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Lack of Assurance of Sterility
- Products
-
- Libtayo (cemiplimab-rwlc) Injection
- Where it was sold
-
USA Nationwide
Nationwide
- Units affected
- 21,353 vials
- About this recall
- Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01